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Abstract  
Occurrence of mutations within the major antigenic alpha determinant region of hepatitis B surface antigen 
(HBsAg can alter HBV antigenicity resulting in   failures in diagnosis, vaccine and hepatitis B immunoglobulin 
therapy. This study aimed at detection of mutations in the “a” determinant region of HBV surface antigen among 
voluntary blood donors in Kenya. This was a cross sectional study involving serology and molecular techniques. 
This study involved analysis of samples from blood transfusion centers. A total of 301 blood samples from donor 
blood were collected for the study.  Sero-status for HBsAg was determined using Enzyme-Linked 
Immunosorbent Assay (ELISA). A fragment of the S gene including the "a" determinant was amplified by PCR 
from the HBsAg positive samples and sequenced for mutation analysis. Mutations and phylogenetic analyses 
were performed using Mega 6 software, Bioedit software and GENETYX® software version 9.1.0. Out of the 
301 samples tested 69/301 (22.9%) were Polymerase Chain Reaction (PCR) positive including 2/69(2.9%) were 
sero-negative for HBsAg. All isolates were genotype A, sub-genotype A1. A total of 29 mutations were observed 
of which 37.9% were located within the “a” determinant. Mutations T143M and K122R were the most frequent 
in this study. Escape mutations associated with diagnostic failure, vaccine and immunoglobulin therapy escape 
were also identified. These findings are important for policies related to vaccine implementation and therapeutic 
and diagnostic guidelines.  
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1. Introduction 
Hepatitis B virus infection (HBV) is a major public health concern especially in Africa, Middle East and Asia 
(Akbar et al., 2004, McMahon, 2005). More than 4 billion people have had contact with HBV worldwide (Ying-
Hui, 2012). Of these, about 360 million people are chronic carriers of HBV that can cause death from liver 
cirrhosis and hepatocellular carcinoma (HCC) (Lavanchy, 2004; WHO, 2015).  
Though HBV is a DNA virus, it replicates via reverse transcriptase (polymerase enzyme) which has no 
proof-reading activity leading to the generation of mutations occurring naturally during infections (Kramvis 
2014). 
Hepatitis B surface antigen (HBsAg) is a primary target for diagnosis and immunoprophylaxis of HBV 
infection (El-sherif et al., 2007). The HBsAg which is a 226 amino acid sequence contains a highly 
conformational, hydrophilic domain known as the “a” determinant located at positions between aa124-aa147 
within the Major Hydrophilic Region (MHR; aa110-aa165 (Hu et al., 2009). The dominant epitopes of “a” 
determinant are the targets of neutralizing antibodies used in active, passive immunization and in diagnostic 
assays. (Kay et al., 2007). Mutations in this region can reduce the binding affinity between the HBsAg and 
antibody to the HBsAg resulting in weak reactivity of serological assays. Although, mutations have been 
described in all the four open reading frames (ORFs) of the HBV, S escape mutants is the most worrying since it 
may be spread by blood transfusion. HBV DNA detection by nucleic acid amplification technology (NAT) is not 
mandatory for blood donor screening in many countries, especially in those areas where the prevalence of S 
escape mutants is projected to be high (Fischinger et al., 2010). It is imperative that the prevalence and types of 
variants of the “a” determinant  found in the population be monitored, because this will affect policy decisions 
relating to vaccine and diagnostic reagents design (Zuckerman, 2000; Francois et al., 2001).To date cases of 
blood donations with diagnostic escape  mutations not detected by HBsAg screening assay have been reported 
(Levicnic, 2004). Therefore, we aimed at detection of mutations in the “a” determinant region within the S gene 
among voluntary blood donors in Kenya. 
 
2. Methods 
This study was cross-sectional where 301 plasma samples were collected from blood transfusion centers in 
Kenya. The samples were then transported to Kenya Medical Research Institute (KEMRI) HBV laboratory 
through cold chain and stored at -80°C till use. The presence of HBsAg was tested using Hepanostika HBsAg 
Ultra (BioMérieux, Lyon, France) kit as per the manufacturer’s instructions.  
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Viral DNA was extracted from 200µl aliquoted plasma using a QIAamp DNA Mini Kit (QIAGEN, 
Hilden, Germany) according to the manufacturer’s instructions. Extracted DNA was eluted in 60µl DNAse free 
water and stored at -20C till use. A 780 base pair (bp) fragment of HBV was amplified by nested PCR using 
Kemtaq DNA polymerase kit from Kenya and HBV specific primer pair S1(LLf) 5’-
TCCTGCTGGTGGCTCCAG-3’as sense primer and S1(LLr) CGTTGACATACTTTCCAATCAA)-3’ as anti-
sense primer (Osilowy et al., 2009). Nested PCR was performed by an ABI Thermocycler 9600 system (Applied 
Biosystems, USA). The conditions for first round PCR consisted of 94 °C for 5 min; followed by 40 cycles at 
94 °C for 4 min; 94 °C for 45 seconds min; and 46 °C for 30 seconds; and final extension at 72 °C for 10 min. A 
total volume of 25µL was amplified in first-round, containing QIAGEN PCR buffer, 0.5µM of each primer, 0.2 
mM dNTP mix, 2.5 U Taq polymerase (KEMRI Taq) and 10µL of extracted DNA. The second PCR round was 
done under the same conditions except that annealing was done at 50°C with 10µl of the first-round product 
using the primer S2nLLf 5’- ACCCTGYRCCGAACATGGA-3’as sense primer and S2 nLLr) 5’- 
CAACTCCCAATTACATARCCCA -3’ as anti-sense primer (Osiowy et al., 2009). PCR-amplified products (10 
µl) were separated by electrophoresis on 2% agarose gel, stained with ethidium bromide and viewed under 
ultraviolet light.  
HBV DNA positive samples were sequenced using a big dye terminator and the obtained nucleotide 
sequences edited and aligned using BioEdit sequence alignment editor software version 5.0.9 (Hall, 1999). The 
newly sequenced (query sequences) were aligned along with reference sequences available in the genbank. This 
was followed by CLUSTAL W multiple sequence alignment (Thompson, 1994). After some manual editing by 
stripping the ends the phylogenetic and molecular evolutionary analyses were conducted using MEGA6 (Tamura 
et al., 2013). The Neighbour-Joining method on the MEGA programme was used to generate a bootstrap 
consensus phylogenetic tree out of a 1000 bootstrap replicates. The nucleotide sequences detected in this study 
were deposited in the GenBank and these are their accession numbers (KR816101-KR816152). The aligned 
nucleotide sequences were translated into amino acid sequences using GENETYX® software version 9.1.0. to 
allow for determination of any mutations  within the S protein.  
Approval to conduct the study was granted by Kenya Medical Research Institute (Kemri) Scientific and 
Ethics Review Unit (SERU) (SSC NO. 2443) and Regional Blood Transfusion Centre. 
 
3. Results 
Hepatitis B Virus DNA PCR was done in 301 samples; PCR amplified 69(22.9%) samples. Of these 2 (2.9%) 
were sero-negative for HBsAg. Table 1 summarizes the ELISA and PCR results. 
The PCR products obtained were sequenced and 52 (75 %) successfully genotyped. A phylogenetic tree 
was generated for all 52 nucleotide sequences as shown in Figure 1. The predominant genotype was A. 
Journal of Biology, Agriculture and Healthcare                                                                                                                                www.iiste.org 
ISSN 2224-3208 (Paper)  ISSN 2225-093X (Online) 
Vol.6, No.14. 2016 
 
3 
0.01
AF046996.1 Woolly monkey
AB179747.1 Japan H
AY090458.F. C.Amer
X75658.F
AY090455 C.America
958
1000
GQ924620.C.Malasy ia
GQ358158.C.INDO
889
AP007262.1 E Japan
AB106564.E.Ghana
1000
GQ377589.1 C D
FJ904433.D.TUN
1998
AB219428.B PHILP
D00331.B JPN
1000
AB056513.1 JPN  G
AF160501.G
1000
GQ184323 SA A2
X70185 Germany A2
998
FN545838 Cameroon A3
EU054331.A.Gabon
JN983876.1 BRZ A1
AY934767 Somalia A1
AB453987 Japan A1
AB076679 Malaw A
AY934772 Uganda A
JN182329.1 SA A1
AM494718 Central  Rep  Afri
AY934773 Tanzania A
828
A1.JX154582.Kenya A1
1230MBS
308NRB
208KSM
1024KSM
1185MBS
213KSM
940NRB
1808
996KSM
978NRB
1039ELD
1134MBS
1115MBS
1177MBS
122NKR
9NKR
312MBS
FM199979 RwandaA1
DQ020002.1 W.AFR  A1
1044ELD
11NKR
1008KSM
1
1014KSM
1KSM
1121MBS
310KSM
118   ELD
108MBS
1158MBS
1223MBS
576NKR
13NKR
16NKR
586NRB
573MBS
982KSM
571MBS
583MBS
574MBS
580NKR
22NKR
21ELD
119NKR
207KSM
2KSM
112MBS
933NRB
587NRB
1041ELD
582MBS
969NRB
972NRB
994KSM
572NRB
20ELD
318MBS
540MBS
7
958
901
 
Figure 1: Phylogenetic analysis based on nucleotide sequencing of the S region. The tree contains sequences 
from 52 samples and a set of representative sequences belonging to genotypes and subgenotypes retrieved from 
Genebank. The phylogenetic tree was constructed using the neighbor-joining method in Clustal W. 
 
3.1 Prevalence of HBV Escape Mutations   
A total 29 mutations were observed in the present study. Eleven of the 29 mutations (37.9%) were located within 
the “a” determinant (124-147), whereas 63.6% (7/11) were in the first loop (positions 120-137) and 36.4% (4/11) 
in the second loop (positions 139-147). The amino acid substitutions detected in the “a” determinant of HBsAg 
included mutations at positions M133I, K133E, M134S, and F137L and T143M in 5 sequences .The most 
frequent mutations observed were T143M and K122R  detected each  in (3/52) 5.8%  of sequences . 
Changes in the Nucleotide and Amino Acid Sequences in the ‘a’ Determinant Region of the HBV S 
Gene. Dots indicate identity to the genotype A consensus. 
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Twenty sequences (38.5%) had  amino acid  changes  outside the ‘a’ determinant identified among them;  
Y161F, E164G W165L, S167L, V184A, T189I, S193L and  A194V.In addition  13 had a single mutation 
(65.0%), 7(35%) had double to triple mutations. 
Table 2:  Distribution of amino acid substitutions in the HBV S gene sequences.  
Amino acid position Wild type amino acid  mutation Frequency 
101 Glutamine/Histidine(Q/H) Histidine(H) 1 
114 Threonine/Lysine(T/K) Lysine(K) 1 
114 Threonine/Serine(T/S) Serine(S) 1 
118 Threonine/Alanine(T/A) Alanine(A) 1 
122 Lysine/Arginine(K/R) Arginine (R) 3 
130 Glysine/Serine(G/S) Serine(S) 1 
133 Methionine/Isoleucine(M/I) isoleucine(I) 1 
133 Lysine/Glutamic Acid(K/E) Glutamic acid(E) 1 
134 Methionine/Serine(M/S) serine(S) 1 
137 Phenylalanine/Leucine(F/L) Leucine(L) 1 
143 Threonine/Methionine(T/M) Methionine(M) 3 
146 Asparagine/Lysine(N/K) Lysine (K) 1 
149 Cysteine/Arginine(C/R) Arginine(R) 1 
159 Alanine/Valine(A/L) Valine(V) 1 
161 Tyrosine/Phenylalanine(Y/F) Phenylalanine(F) 1 
164 Glutamic Acid/Glycine(E/G) Glycine(G) 1 
165 Tryptophan/Leucine(W/L) Leucine(L) 1 
167 Serine/Leucine(S/L) Leucine(L) 2 
184 Valine./Alanine(V/A) Alanine(A) 2 
189 Threonine /Isoleucine(T/I) Isoleucine(I) 1 
193 Serine/Leucine(S/L) Leucine(L) 1 
A194 Alanine/Valine(A/V) Valine(V) 1 
 
4. Discussion 
In this study we report on HBsAg mutations and HBV genotypes among voluntary blood donor population in 
Kenya. Genotype A sub-genotype A1 was observed in all the HBV DNA positive plasma samples tested. This 
was comparable with other published data in Kenya (Kwange et al., 2013). Genotype A was found to be 
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predominant   in Kenya followed by genotypes E and D (Mwangi et al., 2008; Ochwoto et al., 2013).  This 
probably suggest the trends in HBV genotypes has remained the same especially in this study population 
This study also identified mutations of interest in HBV genome. Vaccine escape, immunotherapy and 
diagnostic escape mutants within and outside the “a” determinant region of HBsAg were both detected among 
the volunteer blood donor population. Since the basis for effective prevention of HBV infections lies in the use 
of effective vaccination and diagnostic programming, results of this study therefore provides relevant and 
valuable information on genetic variability of HBV.  
This study found different mutations in the S region of HBV genomes, where the percentage of samples 
with these mutations was 29/52(42.3%). 
In comparison to studies that have been conducted in Kenya Kwange et al., 2013 reported S gene 
mutations including K122R, T189I and S210R in samples collected from various parts of the country. However, 
they did not report any amino acid substitution in “a” determinant. Our finding showed that 37.9% mutations 
were located within the “a” determinant 124-147. 
In a study carried out in Iran (Moradi et al., 2012) the following amino acid changes were reported in 
genotype D: Y100F, L109R, I110L, G112R, S117I, P120S/T, R122K/T, M133I, Y134H, T140I, S143L, G145R, 
G159R, and E164V. Five of 40 mutations (12.5%) occurred in ‘‘a’’ determinant region and they included; 
M133I, Y134H in the first loop of ‘‘a’’ determinant and the rest of substitutions including T140I, S143L and 
G145R occurred in the second loop of ‘‘a’’ determinant. In this study 11 of the 29 mutations (37.9%) were 
located within the “a” determinant, 63.6% (7/11) in the first loop (amino acid positions 120-137) and 36.4% 
(4/11) in the second loop (amino acid positions 139-147).The only similarity that is seen between the two studies 
is amino acid substitutions at M133I which is associated with vaccine escape. The differences might be 
attributed to the difference in genetic variability of HBV.  
Our study reported a pattern of more frequent mutations including K122R and T143M. A mutation 
K122R substitution was detected in three samples within the MHR (aa110-aa165) this is a polymorphism 
typically linked with determining d/y sub-serotype specificity (Martin et al., 2010 ;Amponsah et al., 2013). Two 
previous studies in Kenyan; one by Ochwoto et al., (2013), conducted among liver disease patients and that of 
Kwange et al, 2013 among a blood donor population reported mutations in HBV genome. The current study, 
however reports diversity of mutations within a larger study population and diverse geographical localities in 
Kenya. 
Moreover, Yong et al., 2012 reported mutations at positions D99N, Y100F, Q101R/H, L110I, T113S, 
S114T, S117T, T118M, I126T/V, W165L, and V168A. Our findings showed different feature of mutations with 
four similar mutations at positions Q101H, K122R, T143M, and W165L. This difference could be due to high 
variability of geographical location. 
 A known mutation T143M frequent in this study was reported in Indonesian blood donors and has been 
associated with   altering antigenic properties of variant HBsAg, this mutant also has been associated with 
problems in diagnostic assays and escape to vaccine and HBIg therapy as reported by Le et al., 2010. Here, 
T143M was found in 3 out of 52 samples. Among these samples, two samples were sero-negative for HBsAg but 
positive for the corresponding HBV- DNA. Repeat testing of these samples consistently gave negative results 
despite using different test kits including ELISA and rapid tests. In addition these samples were observed to have 
mutations; T143M, M133I respectively. Since these substitutions has been associated with   failure of HBIg 
therapy and problems in detection assays (Ren et al., 2006). It is likely that failure to detect positivity by 
serology on the samples could be due to mutations. Such reports of false-negative diagnostic results due to 
HBsAg mutants have been described previously (Coleman, 2006; Rebecca, 2011).This could also be due to low 
concentration of analyte. We however did not carry out viral load testing due to unavailability of resources. 
Mutation M133I observed in the present study in one sample was reported in a Spanish study and is 
associated with the failure of HBIg therapy since it causes a reduced HBsAg affinity to anti-HBs and reduced 
HBsAg detection in commercial diagnostic assays (Le et al.2010). Other different amino acid substitutions 
G130S, F137L, T114S, T114K and M134S within MHR were also found in the samples from HBV subtype A1. 
The effects of these variations on the HBsAg are unknown. The other important finding in the current study is 
the magnitude of mutations. In total, 29 mutations were detected in 20 of the 52 samples analyzed. These 
mutations were distributed across the sequenced genome fragment including 11 of 29 in ‘a ‘determinant, 7 and 4 
of 11 in the first and second loop respectively. Since these samples were collected from across different sites in 
Kenya, this probably demonstrates an underlying genotypic mutation dynamics of HBV occurrence in the 
population. The major concern arising from HBsAg mutations is the 3 clinical related outcomes which includes; 
diagnostic escape mutants  affecting reliability of results of various diagnostic assays, escape from vaccine-
induced immunity, antiviral resistance and passively transferred neutralizing responses in newborn babies or 
liver-transplant recipients (Sayiner et al.,2007;Ma, and Wang, 2012). Considerably, these events could be taking 
place in our population undetected, except for blood transfusion, work place, and infants’ vaccination; there is no 
universal policy on HBV prevention in Kenya. This situation could be similar in most countries across Africa. 
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Both genotype variability and mutations are important consideration in development of effective 
vaccines. Hepatitis B virus has been shown to display a certain geographical distribution. Our study however 
indicates a single genotype on all the samples collected from different regions in Kenya. This is however 
understandable since genotype A has been shown to be the most prevalent. Whereas genotypes have been shown 
to influence the disease progression and treatment responses (Bartholomeusz and Schaefer, 2004; Chotiyaputta 
and Lok, 2009). A strong link between HBV genotype and the natural history of disease as well as the better 
response to interferon treatment in genotype A is encouraging. Given the high prevalence of HBV in Kenya, and 
in Africa, where blood transfusion is a critical intervention monitoring and prevention of infections is crucial. 
While mutations in the major hydrophilic region of HBV Surface antigen have been reported in developing 
countries, largely, there is limited data on Hepatitis B in Kenya partly due to lack of official programming, 
universal testing strategy and prioritized research. Currently, the public health impact of Hepatitis is drawing 
attention and the future is likely to see more efforts and focused momentum towards hepatitis. Availability of 
information on mutations and genetic variants of HBV in this region is required to inform development of 
clinical and surveillance mechanisms.  
 
5. Conclusions 
Genotypes A, sub-genotype A1 was found to be prevalent.  Escape mutations which have been associated with 
diagnostic failure, vaccine escape and immunoglobulin therapy are present within the population. Other than 
T143M, different aa substitutions G130S, F137L, T114S, T114K and M134S within MHR were also found in 
the samples from HBV subtype A1. The effects of these variations on the HBsAg are unknown and there is need 
for further studies. This finding is an important monitoring tool in guiding future policies related to laboratory 
diagnostic procedures.  
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